stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / REGN / Net Income

Regeneron Pharmaceuticals, Inc. Net Income 2008–2025

Regeneron Pharmaceuticals, Inc. (REGN) annual net income by fiscal year, computed from SEC filings.

Fiscal yearNet IncomeNet marginChange (YoY)
FY 2025$4.50B31.4%+2.1%
FY 2024$4.41B31.1%+11.6%
FY 2023$3.95B30.1%-8.9%
FY 2022$4.34B35.6%-46.3%
FY 2021$8.08B50.2%+129.9%
FY 2020$3.51B41.3%+66.0%
FY 2019$2.12B32.3%-13.4%
FY 2018$2.44B47.5%+104.0%
FY 2017$1.20B20.4%+33.8%
FY 2016$895.50M18.4%+40.8%
FY 2015$636.06M15.5%+88.1%
FY 2014$338.13M12.0%-18.3%
FY 2013$413.74M19.7%-44.9%
FY 2012$750.27M54.4%+438.3%
FY 2011$-221.76M-49.7%-112.3%
FY 2010$-104.47M-22.8%-54.0%
FY 2009$-67.83M-17.9%+14.3%
FY 2008$-79.13M-33.2%

Source: Regeneron Pharmaceuticals, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Regeneron Pharmaceuticals, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Regeneron Pharmaceuticals, Inc. — frequently asked questions

What is Regeneron Pharmaceuticals, Inc.'s net income?

Regeneron Pharmaceuticals, Inc. (REGN) reported net income of $4.50B for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More REGN financial history

Full REGN fundamentals page → · All 1,500+ companies →